Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients

Covid19 Clinical Trial

— COPS-2003  

Official title:

A Phase 2 Randomized, Double Blinded, Placebo Controlled Study of Oral Camostat Mesilate Compared to Standard of Care in Subjects With Mild-Moderate COVID-19

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04524663
• Other study ID #: 56029
• Status: Completed
• Phase: Phase 2
• Start date: December 19, 2020
• Est. completion date: May 15, 2021

Study information

• Verified date: June 2022
• Source: Stanford University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the efficacy of oral Foipan® (camostat mesilate) compared with the current standard of care in reducing the duration of viral shedding of SARS-CoV-2 virus in patients with mild-moderate COVID-19 disease.

Patients will attend 4 study visits over a period of up to 28 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 49
• Est. completion date: May 15, 2021
• Est. primary completion date: May 15, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Diagnosis of COVID-19 disease as presence of mild-moderate symptoms without signs of respiratory distress, with FDA-cleared molecular diagnostic assay positive for SARS-CoV-2 within 72 hours prior to informed consent

• Males must be sterile, OR agree not to donate semen AND agree to strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication

• Females must be unable to bear children, OR ensure that their male partner is incapable of fathering a child, OR, if of childbearing potential will strictly adhere to contraceptive measures during the study and for seven days following the last dose of study medication

• Females must agree to stop breast-feeding prior to first dose of study drug and through seven days after completing therapy

• Females must have a negative pregnancy test at screening

• Participant agrees to maintain home or other quarantine as recommended by the study physician, except to visit the study site as required by the protocol

Exclusion Criteria:

• Concomitant bacterial respiratory infection documented by respiratory culture. NOTE:

Subjects on empirical antibiotic treatment for possible but unproven bacterial pneumonia, but who are positive for SARS-CoV-2, are allowed in the study.

• Previous use of antiviral drugs that may be active against Covid-19.

• Abnormal laboratory test results at screening:

• Use of adrenocorticosteroids (except topical or inhaled preparations or oral preparations equivalent to or less than 10 mg of oral prednisone) or immunosuppressive or immunomodulatory drugs (e.g., immunosuppressants, anticancer drugs, interleukins, interleukin antagonists or interleukin receptor blockers). NOTE: Treatment of study participants following institutional COVID-19 treatment policies or guidelines, including the use of immunomodulatory medications, is permitted. This excludes treatment with agents that have the potential for direct antiviral activity, including convalescent plasma and NO, and co-enrollment into other clinical studies that evaluate investigational agents for COVID-19.

• Serious chronic disease (e.g., human immunodeficiency virus [HIV], cancer requiring chemotherapy within the preceding 6 months, and/or moderate or severe hepatic insufficiency).

• Previously received camostat mesilate within the past 30 days.

• Advanced kidney disease

• Advanced liver disease

• History of alcohol or drug abuse in the previous 6 months.

• Psychiatric illness that is not well controlled (defined as stable on a regimen for more than one year).

• Taken another investigational drug within the past 30 days.

• Seemed by the Investigator to be ineligible for any reason.

Related Conditions & MeSH terms

• COVID-19
• Covid19

Intervention

Drug:
• Camostat Mesilate
Camostat Mesilate administered as oral tablets
• Placebo
Placebo to match camostat mesilate

Other:
• Standard of Care Treatment
Standard of Care Treatment for COVID-19 Infection

Locations

Country	Name	City	State
United States	Stanford University	Stanford	California

Sponsors (1)

Lead Sponsor	Collaborator
Stanford University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Area Under the Curve (AUC) of Shedding of SARS-CoV-2 Virus	AUC of shedding of SARS-CoV-2 virus calculated using the reverse transcription-polymerase chain reaction (RT-PCR) measures of viral load from self-collected nasal swabs on days 1-10. AUC was defined by a single participant's cycle threshold (Ct) from nasal swabs collected and calculated by the trapezoidal rule, using exact times of collection of each swab. Ct denotes how many PCR cycles are required before the SARS-CoV-2 viral RNA reached a detectable level. Higher Ct values correspond to lower viral copy numbers. For reference, Ct values of 20 correspond to ~2.12 x 106 viral copies per milliliter, while a Ct value of 40 is undetectable and is considered the lower limit of detection of this RT-PCR test for SARS-CoV-2.	Days 1-10
Secondary	AUC of Shedding of SARS-CoV-2 Virus	AUC of shedding of SARS-CoV-2 virus calculated using the RT-PCR measures of viral load from self-collected nasal swabs on days 1-10, 14, 21, and 28. AUC was defined by a single participant's Ct from nasal swabs collected and calculated by the trapezoidal rule, using exact times of collection of each swab. Ct denotes how many PCR cycles are required before the SARS-CoV-2 viral RNA reached a detectable level. Higher Ct values correspond to lower viral copy numbers. For reference, Ct values of 20 correspond to ~2.12 x 106 viral copies per milliliter, while a Ct value of 40 is undetectable and is considered the lower limit of detection of this RT-PCR test for SARS-CoV-2.	Days 1-10, 14, 21, and 28
Secondary	Time Until Cessation of Shedding of SARS-CoV-2 Virus	This outcome is defined as the time in days from randomization to the first negative RT-PCR result of self-collected nasal swabs that is followed by only negative results (i.e. no later positive results are observed).	Up to 28 days
Secondary	Clinical Worsening of COVID-19 Disease in Symptomatic Patients	Number of symptomatic patients with clinical worsening, defined as the development of respiratory distress or symptoms that require hospitalization.	Up to 28 days
Secondary	Time Until Resolution of Symptoms	This outcome is defined as absence of moderate or severe symptoms for at least 24 hours for those reporting moderate or severe symptoms at baseline.	Up to 28 days
Secondary	Development of Antibodies to SARS-CoV-2	Number of patients that develop antibodies to SARS-CoV-2.	Up to 28 days
Secondary	Drug Level on Day Five, One Hour After a Dose Taken on an Empty Stomach		Day 5, 1 hour post dose